Three Biopharma Companies Raise Millions in Separate Series A Financing Rounds

Stablix Therapeutics launched with a $63 million Series A financing round that will be used to develop the company’s and advance a portfolio of protein stabilizers towards the clinic.

New York-based Stablix’s TPS platform, dubbed RESTORED, “generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity,” according to the company announcement.